C-Jun amino terminal kinase 1 deficient mice are protected from streptozotocin-induced islet injury

被引:17
作者
Fukuda, Kyoichi [1 ]
Tesch, Greg H. [1 ,2 ]
Nikolic-Paterson, David J. [1 ,2 ]
机构
[1] Monash Univ, Med Ctr, Dept Nephrol, Melbourne, Vic 3168, Australia
[2] Monash Univ, Med Ctr, Dept Med, Melbourne, Vic 3168, Australia
基金
英国医学研究理事会;
关键词
apoptosis; beta cell; diabetes; hyperglycemia; islet; JNK; macrophage; streptozotocin; T-cell; TNF-alpha;
D O I
10.1016/j.bbrc.2007.12.007
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In vitro studies have implicated the c-Jun amino terminal kinase (JNK) in cytokine-induced pancreatic injury leading to a loss of insulin production and hyperglycemia. We examined the role of JNK1 in the multiple low dose streptozotocin (MLD-STZ) model in which islet injury and hyperglycemia are dependent upon T cell immunity and pro-inflammatory cytokines. MLD-STZ in wild type mice induced islet leukocyte infiltration, cytokine production, P-cell apoptosis, and hyperglycemia. In contrast, Jnk1-/- mice were substantially protected from a loss of insulin producing cells and hyperglycemia in the NILD-STZ model despite a marked islet T cell and macrophage infiltrate. Based upon several lines of evidence, this protection was attributed to a reduction in TNF-alpha production by infiltrating Jnk1-/- macrophages leading to reduced P-cell apoptosis. In conclusion, JNK1 signaling plays an essential role in macrophage induced P-cell apoptosis and the development of hyperglycemia in MLD-STZ induced pancreatic injury. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:710 / 716
页数:7
相关论文
共 25 条
  • [1] The c-Jun amino-terminal kinase pathway is preferentially activated by interleukin-1 and controls apoptosis in differentiating pancreatic β-cells
    Ammendrup, A
    Maillard, A
    Nielsen, K
    Andersen, NA
    Serup, P
    Madsen, OD
    Mandrup-Poulsen, T
    Bonny, C
    [J]. DIABETES, 2000, 49 (09) : 1468 - 1476
  • [2] CYTOTOXICITY OF HUMAN PI-7 INTERLEUKIN-1 FOR PANCREATIC-ISLETS OF LANGERHANS
    BENDTZEN, K
    MANDRUPPOULSEN, T
    NERUP, J
    NIELSEN, JH
    DINARELLO, CA
    SVENSON, M
    [J]. SCIENCE, 1986, 232 (4757) : 1545 - 1547
  • [3] Cell-permeable peptide inhibitors of JNK novel blockers of β-cell death
    Bonny, C
    Oberson, A
    Negri, S
    Sauser, C
    Schorderet, DF
    [J]. DIABETES, 2001, 50 (01) : 77 - 82
  • [4] Mechanisms of pancreatic β-cell death in type 1 and type 2 diabetes -: Many differences, few similarities
    Cnop, M
    Welsh, N
    Jonas, JC
    Jörns, A
    Lenzen, S
    Eizirik, DL
    [J]. DIABETES, 2005, 54 : S97 - S107
  • [5] Defective T cell differentiation in the absence of Jnk1
    Dong, C
    Yang, DD
    Wysk, M
    Whitmarsh, AJ
    Davis, RJ
    Flavell, RA
    [J]. SCIENCE, 1998, 282 (5396) : 2092 - 2095
  • [6] CYTOKINES SUPPRESS HUMAN ISLET FUNCTION IRRESPECTIVE OF THEIR EFFECTS ON NITRIC-OXIDE GENERATION
    EIZIRIK, DL
    SANDLER, S
    WELSH, N
    CETKOVICCVRLJE, M
    NIEMAN, A
    GELLER, DA
    PIPELEERS, DG
    BENDTZEN, K
    HELLERSTROM, C
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (05) : 1968 - 1974
  • [7] A transcriptional inhibitor of TNF-α prevents diabetes induced by multiple low-dose streptozotocin injections in mice
    Holstad, M
    Sandler, S
    [J]. JOURNAL OF AUTOIMMUNITY, 2001, 16 (04) : 441 - 447
  • [8] Macrophage-mediated renal injury is dependent on signaling via the JNK pathway
    Ikezumi, Y
    Hurst, L
    Atkins, RC
    Nikolic-Paterson, DJ
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (07): : 1775 - 1784
  • [9] IMMUNOLOGICAL STUDIES ON THE INDUCTION OF DIABETES IN EXPERIMENTAL-ANIMALS - CELLULAR BASIS FOR THE INDUCTION OF DIABETES BY STREPTOZOTOCIN
    KIM, YT
    STEINBERG, C
    [J]. DIABETES, 1984, 33 (08) : 771 - 777
  • [10] c-Jun NH2-terminal kinase inhibitor anthra(1,9-cd)pyrazol-6(2H)-one reduces inducible nitric-oxide synthase expression by destabilizing mRNA in activated macrophages
    Lahti, A
    Jalonen, U
    Kankaanranta, H
    Moilanen, E
    [J]. MOLECULAR PHARMACOLOGY, 2003, 64 (02) : 308 - 315